CLDN18 and neoplasm: A phase III randomized clinical trial of arcotatug tavatecan monotherapy versus the investigator’s choice of therapy (G-HOPE-001 study, NCT06238843) is recruiting G/GEJAC patients with CLDN18.2 membrane staining of 2+/3+ intensity in at least 75% of tumor cells (Shen et al., 2025).